UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 305

Sortiert nach

A mathematical model of cell equilibrium and joint cell formation in multiple myeloma

Journal of theoretical biology, 2016-02, Vol.390, p.73-79

2016

Volltextzugriff (PDF)

High‐grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis

British journal of haematology, 2008-10, Vol.143 (1), p.71-74

2008

Volltextzugriff (PDF)

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

British journal of haematology, 2005-06, Vol.129 (5), p.607-614

2005

Volltextzugriff (PDF)

The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients

Bone marrow transplantation (Basingstoke), 2008-07, Vol.42 (2), p.105-112

2008

Volltextzugriff (PDF)

Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin

Clinical transplantation, 2011-03, Vol.25 (2), p.222-227

2011

Volltextzugriff (PDF)

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?

Bone marrow transplantation (Basingstoke), 2000-09, Vol.26 (5), p.489-496

2000

Volltextzugriff (PDF)

An elective single autograft with high-dose melphalan: single-center study of 451 patients

Bone marrow transplantation (Basingstoke), 2005-07, Vol.36 (1), p.19-24

2005

Volltextzugriff (PDF)

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study

Bone marrow transplantation (Basingstoke), 2007-01, Vol.39 (2), p.115-120

2007

Volltextzugriff (PDF)

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

Bone marrow transplantation (Basingstoke), 2003-07, Vol.32 (2), p.165-170

2003

Volltextzugriff (PDF)

Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

Bone marrow transplantation (Basingstoke), 2002-05, Vol.29 (10), p.853-859

2002

Volltextzugriff (PDF)

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

British journal of cancer, 2000-07, Vol.83 (1), p.91-94

2000

Volltextzugriff (PDF)

Glomerular filtration rate prior to high-dose melphalan 200 mg/m as a surrogate marker of outcome in patients with myeloma

British journal of cancer, 2001-08, Vol.85 (3), p.325-332

2001

Volltextzugriff (PDF)

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

Haematologica (Roma), 2007-08, Vol.92 (8), p.1149-1150

2007

Volltextzugriff (PDF)

Red cell fragmentation (schistocytosis) after bone marrow transplantation

Bone marrow transplantation (Basingstoke), 1998-10, Vol.22 (8), p.777-780

1998

Volltextzugriff (PDF)

Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation

Bone marrow transplantation (Basingstoke), 2000-03, Vol.25 (5), p.501-505

2000

Volltextzugriff (PDF)

Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?

Bone marrow transplantation (Basingstoke), 2003-07, Vol.32 (2), p.157-164

2003

Volltextzugriff (PDF)

Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia

Bone marrow transplantation (Basingstoke), 1999-03, Vol.23 (5), p.523-525

1999

Volltextzugriff (PDF)

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

Bone marrow transplantation (Basingstoke), 2001-07, Vol.28 (1), p.29-37

2001

Volltextzugriff (PDF)

Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)

Bone marrow transplantation (Basingstoke), 1999-04, Vol.23 (8), p.803-807

1999

Volltextzugriff (PDF)

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?

Bone marrow transplantation (Basingstoke), 2002-10, Vol.30 (8), p.479-484

2002

Volltextzugriff (PDF)

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

Bone marrow transplantation (Basingstoke), 1999-04, Vol.23 (7), p.675-680

1999

Volltextzugriff (PDF)

Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning : Follow-up of 725 patients from a single centre over a period of 26 years

Bone marrow transplantation (Basingstoke), 2000-02, Vol.25 (4), p.365-370

2000

Volltextzugriff (PDF)

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants

Blood, 2000-06, Vol.95 (12), p.3683-3686

2000

Volltextzugriff (PDF)

Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma : a phase I/II feasibility and tolerance study of 17 patients

Bone marrow transplantation (Basingstoke), 2000-05, Vol.25 (9), p.949-956

2000

Volltextzugriff (PDF)

The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients

Medical oncology (Northwood, London, England), 2001-01, Vol.18 (1), p.39

2001

Volltextzugriff (PDF)

1 – 25 von 305

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(237)
Mit Volltextzugriff
(264)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

2 weitere anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

A mathematical model of cell equilibrium and joint cell formation in multiple myeloma

High‐grade transformation in splenic marginal zone lymphoma with circulating villous lymphocytes: the site of transformation influences response to therapy and prognosis

Long‐term outcomes of previously untreated myeloma patients: responses to induction chemotherapy and high‐dose melphalan incorporated within a risk stratification model can help to direct the use of novel treatments

The role of maintenance chemotherapy after autotransplantation for acute lymphoblastic leukemia in first remission: single-center experience of 100 patients

Mycophenolic acid trough level monitoring: relevance in acute and chronic graft versus host disease and its relation with albumin

A low CD34+ cell dose results in higher mortality and poorer survival after blood or marrow stem cell transplantation from HLA-identical siblings: should 2 x 10(6) CD34+ cells/kg be considered the minimum threshold?

An elective single autograft with high-dose melphalan: single-center study of 451 patients

Use of physiological doses of human growth hormone in haematological patients receiving intensive chemotherapy promotes haematopoietic recovery: a double-blind randomized, placebo-controlled study

Thalidomide after allogeneic haematopoietic stem cell transplantation: activity in chronic but not in acute graft-versus-host disease

Does donor-recipient ABO incompatibility protect against relapse after allogeneic bone marrow transplantation in first remission acute myeloid leukemia?

Secondary myelodysplastic syndrome/acute myeloid leukaemia following mitoxantrone-based therapy for breast carcinoma

Glomerular filtration rate prior to high-dose melphalan 200 mg/m as a surrogate marker of outcome in patients with myeloma

The combination of cyclophosphamide, velcade and dexamethasone (CVD) induces high response rates with comparable toxicity to velcade alone (V) and velcade plus dexamethasone (VD)

Red cell fragmentation (schistocytosis) after bone marrow transplantation

Comparison of marrow and blood cell yields from the same donors in a double-blind, randomized study of allogeneic marrow vs blood stem cell transplantation

Impact of cytogenetics on the outcome of autotransplantation for acute myeloid leukemia in first remission: is the benefit of intensive pretransplant therapy limited to patients with good karyotypes?

Vaginal stenosis following allogeneic bone marrow transplantation for acute myeloid leukaemia

Comparison of new patients with Bence-Jones, IgG and IgA myeloma receiving sequential therapy: the need to regard these immunologic subtypes as separate disease entities with specific prognostic criteria

Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD)

Collection of peripheral blood stem cells in newly diagnosed myeloma patients without any prior cytoreductive therapy: the first step towards an 'operational cure'?

Impact of previous high-dose therapy on outcome after allografting for multiple myeloma

Melphalan/TBI is not more carcinogeneic than cyclophosphamide/TBI for transplant conditioning : Follow-up of 725 patients from a single centre over a period of 26 years

Chronic graft versus host disease is associated with long-term risk for pneumococcal infections in recipients of bone marrow transplants

Acute lymphoblastic leukaemia-type intensive chemotherapy to eliminate minimal residual disease after high-dose melphalan and autologous transplantation in multiple myeloma : a phase I/II feasibility and tolerance study of 17 patients

The implication of compromised renal function at presentation in myeloma: similar outcome in patients who receive high-dose therapy: a single-center study of 251 previously untreated patients

Suchergebnisse filtern